The carcinoGENOMICS project: critical selection of model compounds for the development of omics-based in vitro carcinogenicity screening assays.

Autors de IIS La Fe

• José Vicente Castell Ripoll

  Autor

• Bernardo Roque Bort Martí

  Autor

• María Teresa Donato Martín

  Autor

Autors aliens a IIS La Fe

• Vinken M
• Doktorova T
• Ellinger-Ziegelbauer H
• Ahr HJ
• Lock E
• Carmichael P
• Roggen E
• van Delft J
• Kleinjans J
• Ryan M
• Corvi R
• Keun H
• Ebbels T
• Athersuch T
• Sansone SA
• Rocca-Serra P
• Stierum R
• Jennings P
• Pfaller W
• Gmuender H
• Vanhaecke T
• Rogiers V

Grups d'Investigació

• Hepatología experimental y Trasplante hepático

  Investigador Principal

  Laia Tolosa Pardo

• Unidad Mixta de Investigación en Hepatología Experimental

  

  Investigador Principal

  Ramiro Jover Atienza

Abstract

Recent changes in the European legislation of chemical-related substances have forced the scientific community to speed up the search for alternative methods that could partly or fully replace animal experimentation. The Sixth Framework Program project carcinoGENOMICS was specifically raised to develop omics-based in vitro screens for testing the carcinogenic potential of chemical compounds in a pan-European context. This paper provides an in-depth analysis of the complexity of choosing suitable reference compounds used for creating and fine-tuning the in vitro carcinogenicity assays. First, a number of solid criteria for the selection of the model compounds are defined. Secondly, the strategy followed, including resources consulted, is described and the selected compounds are briefly illustrated. Finally, limitations and problems encountered during the selection procedure are discussed. Since selecting an appropriate set of chemicals is a frequent impediment in the early stages of similar research projects, the information provided in this paper might be extremely valuable.